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ABSTRACT: Antimicrobial resistance is a major threat the world is currently facing. Development of new antibiotics and the
assessment of their toxicity represent important challenges. Current methods for addressing antibiotic toxicity rely on measuring
mitochondrial damage using ATP and/or membrane potential as a readout. In this study, we propose an alternative readout
looking at changes in the lipidome on intact and unprocessed cells by matrix-assisted laser desorption ionization mass
spectrometry. As a proof of principle, we evaluated the impact of known antibiotics (levoﬂoxacin, ethambutol, and kanamycin)
on the lipidome of HeLa cells and mouse bone marrow-derived macrophages. Our methodology revealed that clinically relevant
concentrations of kanamycin alter the ratio of cardiolipins to phosphatidylinositols. Unexpectedly, only kanamycin had this
eﬀect even though all antibiotics used in this study led to a decrease in the maximal mitochondrial respiratory capacity.
Altogether, we report that intact cell-targeted lipidomics can be used as a qualitative method to rapidly assess the toxicity of
aminoglycosides in HeLa and primary cells. Moreover, these results demonstrate there is no direct correlation between the ratio
of cardiolipins to phosphatidylinositols and the maximal mitochondrial respiratory capacity.
■ INTRODUCTION
Given their potential side eﬀects, antibiotics can be a double-
edged sword. For instance, aminoglycosides can cause hearing
loss as well as kidney damage in humans.1,2 Several lines of
evidence have demonstrated that clinically relevant doses of
antibiotics induce the formation of reactive oxygen species
(ROS) and mitochondrial dysfunction in mammalian cells, due
to disruption of the tricarboxylic acid (TCA) cycle and the
electron transport chain (ETC).3−7 Thus, assessment of
antibiotic toxicity is a crucial factor to address in drug discovery.
For example, troglitazone,8 an antidiabetic and anti-inﬂamma-
tory drug, and cerivastatin,9 a member of the class of cholesterol-
lowering drugs, were withdrawn from the market in the early
2000s because of their toxicity to mitochondrial function.
Importantly, between 1994 and 2006, 38 antibiotics approved
by the U.S. Food and Drug Administration were withdrawn,
representing ∼2% of the total drugs commercially available.10,11
Therefore, there is an urgent need to not only develop better
antibiotics but also to select antibiotics that do not generate
ROS, mitochondrial damage, or other negative side eﬀects.
Currently, a variety of commercially available assays are available
to measure the eﬀect of antibiotic toxicity in mitochondria,
based on measurements of ATP levels or changes in membrane
potential. Moreover, other technologies can assess antibiotic
toxicity by measuring mitochondrial oxygen consumption using
oxygen sensors and time-resolved ﬂuorescence. However, these
solutions can be time-consuming and expensive. In this study,
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we propose a new method for assessing antibiotic toxicity based
on intact cell lipid proﬁling. Antibiotics can alter the central
carbon metabolism and therefore the TCA cycle and the ETC,
which consequently leads to a decrease in metabolic activity and
changes in metabolic pathways.12,13 Among these metabolic
pathways, we reasoned that fatty acid synthesis can be altered as
a result of a changes in the TCA cycle activity, and as a
consequence an alteration of available levels of acetyl-coenzyme
A required for lipids synthesis. We therefore propose that
changes in the TCA cycle activity could lead to a remodeling of
the cell lipidome, and these changes can be used as potential
markers of antibiotic toxicity. The cell lipidome includes lipids
such as phospholipids (PLs), phosphatidylinositols (PI), and
cardiolipins (CL). CL or diphosphatidylglycerols are found
almost exclusively in the inner membrane of the mitochondria
and are associated with enzymes and oxidative phosphorylation
complexes involved in ATP biosynthesis and the maintenance of
the ETC.14,15 We thus hypothesize that lipidomics and high-
throughput technologies can be used as an alternative to probe
changes in the relative abundance of PI and CL as a readout of
mitochondrial damage resulting from antibiotic toxicity. To
have access to the entire lipidome and because of the
heterogeneity of the lipids, extraction procedures (which enrich
lipids and prefractionate them) can be crucial for evaluating the
changes in the lipidome.16−20 The conventional separation of
lipid classes is predominantly achieved by diﬀerential solvent
extraction, followed by silica thin-layer chromatography, gas
chromatography, or liquid chromatography such as normal-
phase or hydrophobic interaction liquid chromatography
(HILIC).21−23 Over the past decade, the capabilities of
matrix-assisted laser desorption ionization mass spectrometry
(MALDI-MS) in lipid analysis have been demonstrated for the
analysis of lipid extracts from diﬀerent biological materials.24−28
However, the most promising advantage of the MALDI-MS
technique is performing lipid analysis avoiding extraction and/
or separation steps, called intact cell lipidomics (ICL). ICL is
highly valuable for lipids that are tightly bound to membrane
proteins (e.g., CL) and may be diﬃcult to completely recover in
lipid extracts. For example, Angelini and colleagues reported the
analysis of lipidomics of yeast (Saccharomyces cerevisae) and
bovine heart mitochondria by ﬁrst isolating mitochondria
followed by direct MALDI-MS using the matrix 9-amino
acridine solubilized in the organic solvents 2-propanol and
acetonitrile in a 6:4 (v/v) ratio.24 In this case, they could identify
in the negative ion mode phosphatidic acid (PA), phosphati-
dylserine (PS), phosphatidylglycerol (PG), phosphatidyletha-
nolamine (PE), PI, and CL. As another example, Jones and
colleagues performed ICL on yeast by MALDI-Fourier
transform-MS in untreated yeast using a saturated solution of
the matrix 2,5-dihydroxybenzoic acid dissolved in a 9:1 (v/v)
methanol/water mixture, allowing the detection in the positive
ion mode of phosphatidylcholine (PC), PI, PE, and PA.29
Although highly promising, the study by Angelini and colleagues
relies on isolation of organelles (such as the mitochondria or
membranes), which is incompatible with high-throughput
screening (HTS) for assessing antibiotic toxicity and mitochon-
drial damage. Furthermore, the study by Jones and colleagues
includes several steps of sample preparation prior to ICL. As
such, several washes with the appropriate buﬀer followed by
suspension of the pellet in 50% methanol are required prior to
ICL, and the solution must be deposited within 10 min on the
target, making this sample preparation challenging for HTS. So
far, studies have never investigated lipidome remodeling in
response to a trigger using ICL on intact nonprocessed
eukaryotic cells. We recently reported bacterial lipidomics on
intact mycobacteria and Enterobacteriacae without any isolation
of membranes or subcellular compartments, and without any
sample preparation other than directly loading the samples on
the MALDI target followed by the addition of the matrix
solubilized in organic solvents.30,31 Considering this success, we
sought to apply a similar approach to intact untreated and
antibiotic-treated eukaryotic cells to evaluate the potential of
this technology in the assessment of the eﬀect of the antibiotic
on the lipidome. In this study, we chose two cell types, a cell line
and primary cells. HeLa cells, a human epithelial immortal cell
line, are used as model for this study because of their widespread
use for the investigation of host−pathogen interactions. HeLa
cells can be invaded by a wide variety of well-studied
enteropathogens, such as Salmonella, Shigella, Listeria, and
Yersinia.32−35 Mouse bone marrow-derived macrophages
(BMDM) are primary cells widely used to study host−pathogen
interactions, too. As a proof of principle and to demonstrate the
potential of ICL, we focused on determining the impact on the
targeted lipidome on cells treated with the aminoglycoside,
kanamycin. Kanamycin is an antibiotic that blocks protein
synthesis by binding to the bacterial ribosomal subunit.36
Kanamycin is broadly used to treat severe bacterial infection
worldwide but has been associated with drastic side eﬀects. To
evaluate the speciﬁcity of kanamycin’s impact on the lipidome of
the cells, we also used two other antibiotics with diﬀerent modes
of action, the ﬂuoroquinolone levoﬂoxacin37,38 that inhibits
bacterial DNA gyrase and DNA topoisomerase IV39 and
ethambutol40 that targets the arabinosyltranferases EMBs
involved in arabinogalactan biosynthesis, which is a major
constituent of the mycobacterial cell wall.41 Importantly, all
antibiotics employed in this study are currently used for the
treatment of bacterial infections in clinics. The concentrations
used in our study were chosen according to the peak of antibiotic
concentration found in the serum (Cmax) of patients treated with
these antibiotics.6,37,38,40,42 Remarkably, by using ICL on intact
HeLa and BMDM cells, we found that the ratio of CL to PI is
impaired upon treatment with clinically relevant concentrations
of kanamycin and high levels of levoﬂoxacin (5Cmax). However,
by investigating mitochondrial respiration, we found, for the ﬁrst
time, no direct correlation between the CL:PI ratio and
mitochondrial damage.
■ MATERIALS AND METHODS
HeLa Cell Growth Conditions. HeLa (ATCC CCL) cells were
maintained in Dulbecco’s minimal essential medium (DMEM, Gibco
by Life Technologies) supplemented with 10% heat-inactivated fetal
bovine serum at 37 °C. Cells (1−5 × 105 cells/mL, which is the lowest
limit for performing the experiments) were seeded into 24-well tissue
culture plates (Corning). Cells were allowed to adhere overnight, then
scraped oﬀ, and washed three times with 500 μL of doubly distilledH2O
(ddH2O) by centrifuging them at 15,000 × g for 5 min and carefully
discarding the supernatant. The ﬁnal pellet was resuspended in 100 μL
of ddH2O.
Isolation of Mouse Bone Marrow-Derived Macrophages.
Bonemarrow cells were ﬂushed from the femur and tibia of 8−10-week-
old female BALB/cmice and diﬀerentiated into macrophages for 7 days
in RPMI 1640 (Gibco) supplemented with 1 mM sodium pyruvate
(Gibco), 2 mM L-glutamine (Lonza), 0.05 M 2-mercaptoethanol
(Gibco), 10% heat-inactivated fetal bovine serum (Biosera), and 20%
L-cell conditioned media. On day 4, cells were fed with an additional 10
mL of media. After being cultured for 7 days, cells were washed with
phosphate-buﬀered saline (PBS) and seeded at a density of 5 × 105
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cells/mL for lipidomics and the Seahorse XF cell mito stress test and
9,000 cells/well for cell viability assays.
Seahorse XF Cell Mito Stress Test.Mouse bone marrow-derived
macrophages and HeLa cells were seeded on an eight-well miniplate at
cell densities of 5 × 105 and 1.5 × 105 cells/mL, respectively, and left to
adhere overnight. Cells were or were not treated with antibiotics, and
after 24 h, the oxygen consumption rate (OCR) was measured using a
Seahorse XFp extracellular ﬂux analyzer (Seahorse Bioscience). The
day before the assay, the sensor cartridge was hydrated by ﬁlling the
utility plate with 200 μL of sterile ddH2O and incubating overnight at
37 °C in a non-CO2 incubator. On the day of the assay, the water was
replaced with 200 μL of prewarmed XF Calibrant (Agilent) and
incubated for 1 h at 37 °C in a non-CO2 incubator. Also, on the day of
the assay, the culture medium was replaced with 180 μL of unbuﬀered
Seahorse XF medium [DMEM with phenol red supplemented with 10
mM glucose, 1 mM sodium pyruvate, 2 mM glutamine, and phenol red
pH 7.4], and the cells were incubated at 37 °C in a non-CO2 incubator
for 45 min. Baseline rates were measured at 37 °C three times before
sequentially injecting the following mitochondrial inhibitors: oligomy-
cin (10 μM), carbonyl cyanide p-(triﬂuoromethoxy) phenylhydrazone
(FCCP, 20 μM), and a rotenone/antimycin A mixture (5 μM). After
the addition of each inhibitor, three readings were taken. OCR was
automatically calculated by the Seahorse XFp software. Every point
represents an average of three diﬀerent wells.
Cell Viability Assay. Cell viability was assessed using Alamar Blue
Cell Viability Reagent (catalog no. DAL1025) purchased from Thermo
Fisher Scientiﬁc and by following themanufacturer’s instructions; 9,000
cells per well were seeded on a black, clear bottom 96-well plate
(Corning). Cells were or were not treated with antibiotics for 24 h; 5%
DMSO (Sigma) in medium was used as a positive control. The
ﬂuorescence intensity was monitored using a HIDEXmicroplate reader
with excitation and emission wavelengths set at 544 and 590 nm,
respectively. The assay was performed in quadruplicate and repeated
three times.
Antibiotic Treatments. Cells were treated for 24 h at 37 °C in an
incubator with 5% CO2 with
1/5Cmax, Cmax, and 5Cmax corresponding to
0.8, 4, and 20 μg/mL for ethambutol, 5, 25, and 125 μg/mL for
kanamycin, and 2.2,, 11, and 55 μg/mL for levoﬂoxacin, respectively.
After being exposed for 24 h, cells were then used for further analysis.
MALDI-MS Analysis. Prior to mass spectrometry analysis, the
super-2,5-dihydroxybenzoic acid (Sigma-Aldrich, catalog no. 50862)
matrix was added at a ﬁnal concentration of 10mg/mL in a chloroform/
methanol mixture at a 90:10 (v/v) ratio; 0.4 μL of a cell solution at a
concentration of 2 × 105 to 2 × 106 mL−1, corresponding to ∼100−
1000 cells per well of the MALDI target plate (384 Opti-TOF 123 mm
× 84 mm AB Sciex NC0318050, 1016629), and 0.6 μL of the matrix
solution were deposited on the MALDI target plate, mixed with a
micropipette, and left to dry gently. MALDI-TOF MS analysis were
performed on a 4800 Proteomics Analyzer (with TOF-TOF Optics,
Applied Biosystems) using the reﬂectron mode. Samples were analyzed
operating at 20 kV in the negative ion mode, and three independent
experiments were performed. Mass spectrometry data were analyzed
using Data Explorer version 4.9 from Applied Biosystems. Assignments
were based on the MS/MS fragmentation proﬁle and CL standards
from bovine heart (Sigma-Aldrich, catalog no. C0563).
Membrane Potential Measurement. 6,000 HeLa cells per well
were seeded on a black sterile 96-well plate with a clear ﬂat bottom.
After 24 h, cells were treated with 25 μg/mL kanamycin for 24 h and
changes in membrane potential were measured by ﬂuorescence with
excitation at 475 nm and emission at 530 nm following the protocol of
the JC-1-Mitochondrial Membrane potential assay kit and as
recommended by the manufacturer (ab113850).
Preparation ofMicroscopy Samples.HeLa cells were plated (1−
5 × 105) on glass coverslips in six-well plates (Thermo Scientiﬁc) and
used for experiments 24 h later. HeLa cells were treated with 25 μg/mL
kanamycin for 24 h and incubated with 0.1 μM MitoTrackerTM Red
CMXRos for 30 min prior to ﬁxation. HeLa cells were washed with 1×
PBS and ﬁxed in 4% paraformaldehyde (PFA) for 15 min at room
temperature. Then, cells were washed with 1× PBS, incubated for 10
min in 1 μg/mL DAPI, and mounted in aqua polymount mounting
medium (Polyscience Inc.).
Microscopy. Samples were imaged on an Axiovert Z1 instrument
driven by ZEN software (Carl Zeiss MicroImaging) taking Z-stack
image series using a 63× oil objective. Image deconvolution was
performed using ZEN software, and mitochondrial morphology was
analyzed using the MiNA-master plugin for FIJI. At least 100 cells per
experiment from three independent experiments were used for analysis.
Image processing was performed in Icy (http://icy.bioimageanalysis.
org).
Statistical Analysis. Data are presented as means ± the standard
error of the mean from at least three independent experiments and
three technical replicates per condition for power calculation. Student’s
Figure 1. Lipid ﬁngerprint of intact HeLa cells byMALDI-MS. (A)Negative ionmodeMALDI-TOFMS spectra of intact untreatedHeLa cells at 24 h.
(B)Negative ionmodeMALDI-TOFMS spectra of intact HeLa cells treated with 25 μg/mL kanamycin for 24 h. Compared to untreatedHeLa cells in
panel A, where the major peak is at m/z 885.4, in kanamycin-treated cells, the major peak is at m/z 861.4, demonstrating a change in PI metabolism
upon treatment with kanamycin compared to untreated HeLa cells.
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t tests were used to compare values, with p < 0.05 being considered
signiﬁcant. Ratios of changes (e.g., CL:PI ratio, cell viability, and
membrane potential) were determined compared to untreated cells,
and the standard deviation was calculated according to the error
propagation in calculated ratios.43
■ RESULTS AND DISCUSSION
ICL Identiﬁed Changes in the CL:PI Ratio in
Kanamycin-Treated HeLa Cells. To detect PIs and CLs
(which are negatively charged molecules) by ICL, the mass
spectra of lipids of intact HeLa cells in the absence or presence of
kanamycin were acquired in the negative ion mode using super-
2,5-dihydroxybenzoc acid as the matrix (Figure 1A,B). This
matrix was chosen because of its versatility for the analysis of
phospholipids.44
In the negative ion mode, for both untreated and kanamycin-
treated (25 μg/mL for 24 h) HeLa cells, all signals in the mass
spectrum can be attributed to the [M −H]−molecular ions and
fall into twomain categories. The peaks can be grouped into two
main m/z ranges: (i) m/z 800−950, attributable to major PIs,
and (ii)m/z 1300−1500, attributable to CLs. In the range ofm/
z 700−950, consisting of major PIs, the peaks at m/z 835.4,
861.4, 863.4, 885.4, and 911.5 are assigned to PI 34:1, 36:2, 36:1,
38:4, and 40:4, respectively, and supported by their MS/MS
proﬁle (Figure.S1). In the CL range, the major peaks at m/z
1399.8 and 1427.8 can be attributed to CL 68:4 and 70:4 where
the major species are CL(16:1/C18:1)2 and CL(16:1/C18:1/
18:1/18:1), respectively, and are supported by their MS/MS
proﬁle (Figures S2 and S3). These data are consistent with
results from published lipidome analysis24,29 but here are
generated on intact and unprocessed biological samples.
However, as compared to untreated cells, kanamycin-treated
cells signiﬁcantly changed the relative abundance of main PI
lipids, with an increase in PI lipids containing shorter fatty acid
chain lengths at m/z 835.4, 861.4, and 863.4 compared to m/z
885.4, as an internal reference (Figure 1B). By using the ratio of
the sum of the abundance of PI 34:1, 36:2, and 36:1 to PI 38:4, a
25% increase in this ratio can be observed in the presence of
kanamycin, compared to that in untreated cells (Figure 2A).
Furthermore, a 40% decrease in the CL:PI ratio is observed in
kanamycin-treated cells at 24 h, as compared to that in untreated
cells (Figure 2B). Taken together, these data support an
alteration in PI metabolism in response to kanamycin treatment.
In summary, these data show that kanamycin treatment
results in the production of PI containing shorter fatty acids and
alteration of the CL:PI ratio. These results suggest an
impairment of the bioenergetics of mitochondria caused by a
decrease in the TCA cycle activity and fatty acid synthesis.
Kanamycin Alters the Membrane Potential and
Mitochondrial Morphology in HeLa Cells. PLs (PI and
CL) are associated with membranes that can generate an
electrochemical gradient involved in mitochondrial bioenergetic
processes. Considering that mitochondrial energy metabolism is
tightly linked to organelle function, disruption of the ETC
should lead to a decrease in the mitochondrial membrane
potential, ATP levels, and overall metabolic activity.45,46
Membrane potential measurements provide information about
the coupling of electron transfer to ATP synthesis, as well as the
organelle’s ability to take up and release ions and substrates
across the mitochondrial inner membrane. We therefore
performed mitochondrial membrane potential measurements
to conﬁrm that the observed lipid changes are due to disrupted
mitochondrial bioenergetics and not an indirect eﬀect of our
experimental design.
HeLa cells were treated for 24 h with 25 μg/mL kanamycin,
and the mitochondrial membrane potential was measured and
expressed as a ratio compared to untreated cells (Figure 3). In
this case, we observed a 20% decrease in themembrane potential
compared to that of untreated cells, which is consistent with
observations from the literature.6 Comparison of the membrane
potential of a control with that of FCCP [carbonyl cyanide 4-
(triﬂuoromethoxy) phenylhydrazone], an ionophore uncoupler
of oxidative phosphorylation, showed it decreased by 60%
Figure 2. Kanamycin at 25 μg/mL for 24 h induces changes in
phospholipids in HeLa cells. (A) Ratio of the sum of the abundance of
PI (34:1, 36:2, and 36:1) to PI 38:4. (B) Ratio of CL to PI lipids. Black
bars represent time zero, and gray bars represent 24 h. *p < 0.05 and
**p < 0.005, as analyzed by a Student’s t test.
Figure 3. Mitochondrial membrane potential of HeLa cells after
treatment for 24 h with 25 μg/mL kanamycin. *p < 0.05 and **p <
0.005, as analyzed by a Student’s t test.
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compared to that of untreated cells. To further validate our
methodology, we investigated possible changes in mitochondrial
morphology after kanamycin treatment using microscopy to
determine the number of mitochondrial branches and their
length as a readout of changes in mitochondrial bioenergetics.
Eﬀectively, more and longer branches presented by mitochon-
dria may represent a larger surface area, suggesting a higher level
of potential energy to be spent. Smaller mitochondria and
mitochondria with simpler shapes would suggest a decrease in
their energy level.47 To investigate this, HeLa cells were or were
not treated with kanamycin (25 μg/mL for 24 h). Untreated
cells showed longer and highly branched mitochondria, whereas
cells treated with kanamycin presented shorter and less
branched mitochondria (Figure 4). In particular, mitochondrial
branch lengths were signiﬁcantly shorter and the number of
branches was smaller in kanamycin-treated HeLa cells than in
the untreated ones (Figure 4B,C).
Collectively, these data show that a clinically relevant
concentration of kanamycin alters mitochondrial morphology
and membrane potential.
ICL Probed Whether Kanamycin but Not Levoﬂoxacin
or Ethambutol Induces Changes in the CL:PI Ratio in a
Dose-Dependent Manner in HeLa Cells and BMDM. To
investigate if the changes in the CL:PI ratio were speciﬁc to the
Figure 4. Mitochondrial morphology in untreated and kanamycin-treated HeLa cells. (A) HeLa cells were left untreated (UT) and treated with
kanamycin for 24 h (Kan). Mitochondrial morphology was analyzed inHeLa cells usingMitoTracker Red CMXros. The scale bar represents 5 μm. (B)
Mitochondrial branch length measured using the MiNA-master plugin for FIJI. This graph shows median and whiskers (minimum to maximum). (C)
Number of mitochondrial branches determined using the MiNA-master plugin for FIJI. This graph shows median and whiskers (minimum to
maximum). ***p < 0.001, as analyzed by a Student’s t test.
Figure 5.CL:PI ratios at 1/5Cmax, Cmax, and 5Cmax for HeLa cells and BMDM cells treated with levoﬂoxacin (A and D, respectively), ethambutol (B and
E, respectively), and kanamycin (C and F, respectively). *p < 0.05 and **p < 0.005, as analyzed by a Student’s t test.
Chemical Research in Toxicology Article
DOI: 10.1021/acs.chemrestox.8b00038
Chem. Res. Toxicol. 2018, 31, 688−696
692
kanamycin exposure of HeLa cells for 24 h or to lipidome
remodeling in response to antibiotic exposure, we conducted a
series of ICL experiments by determining the CL:PI ratio of
HeLa to BMDM cells after a 24 h exposure to levoﬂoxacin,
ethambutol, or kanamycin, each antibiotic having a diﬀerent
mode of action. We evaluated the CL:PI ratio after antibiotic
treatment for 24 h using both HeLa and BMDM cells (primary
cells), as they diﬀer in their primary carbon metabolism. While
Figure 6. HeLa cells (A−C) and BMDM cells (D−F) viability expressed as a ratio of antibiotic-treated cells (1/5Cmax, Cmax, and 5Cmax) to untreated
cells. Cells treated with levoﬂoxacin (A and D), ethambutol (B and E), and kanamycin (C and F).
Figure 7.Maximal mitochondrial oxygen consumption in HeLa cells untreated and treated with kanamycin (A), levoﬂoxacin (B), and ethambutol (C)
and BMDMcells untreated and treated with kanamycin, levoﬂoxacin, and ethambutol atCmax (D).*p < 0.05 and **p < 0.005, as analyzed by a Student’s
t test.
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immortalized cell lines such as HeLa cells catabolize glucose
through the Embden−Meyerhof−Parnas pathway, the pentose
phosphate pathway, and to a lesser extent the TCA cycle
(Warburg eﬀect), primary cells mainly employ the TCA
cycle.48−50 This can have major consequences for how the
cells can respond to antibiotic stress exposure and so for the
CL:PI ratio.
In bothHeLa and BMDMcells, only 5Cmax of levoﬂoxacin (55
μg/mL) alters the CL:PI ratio with a 2.8-fold decrease in HeLa
cells and 1.5-fold decrease in BMDM cells (Figure 5). In
addition, in bothHeLa and BMDMcells, for allCmax values used,
ethambutol exposures of 24 h do not alter the CL:PI ratio.
However, in HeLa cells, kanamycin induces changes in the
CL:PI ratio at Cmax and 5Cmax with similar orders of magnitude
with an∼1.5-fold decrease in the CL:PI ratio. This eﬀect is more
pronounced in primary cells, where a dose dependence is
noticed. In this case, at Cmax, the CL:PI ratio decreases by 1.4-
fold and by 2.5-fold at 5Cmax. Taken together, discovered from
use of ICL, these data suggest that only kanamycin at Cmax
induces changes in the CL:PI ratio.
Kanamycin, Levoﬂocaxin, and Ethambutol Do Not
Aﬀect HeLa Cells or BMDMViability at Cmax and 5Cmax.To
determine if the changes in the CL:PI ratio were due to the
diﬀerence in cell viability, we tested cell survival after 24 h
exposure to the antibiotics. In this case, in terms of cell viability,
no statistically signiﬁcant diﬀerences were observed across all
antibiotics and concentrations tested (Figure 6). These data
conﬁrm the hypothesis that changes in the CL:PI ratio are due to
the antibiotic exposure and not due to cell apoptosis.
Kanamycin, Levoﬂocaxin, and Ethambutol Decrease
the Maximal Rate of Mitochondrial Respiration. To test
whether changes in the CL:PI ratio can directly correlate with
mitochondrial dysfunction, we measured the maximal mito-
chondrial respiratory capacity on HeLa cells or BMDM cells
treated with kanamycin, levoﬂoxacin, and ethambutol at 1/5Cmax,
Cmax, and 5Cmax for HeLa cells and Cmax for BMDM cells. We
monitored changes in the oxygen consumption rate (OCR) of
intact HeLa cells and BMDM using the Agilent Seahorse XF cell
mito stress test. This assay measures directly the OCR and uses
modulators of cellular respiration that speciﬁcally target
components of the ETC to reveal key parameters of metabolic
function. The compounds, oligomycin, FCCP, and a mix of
rotenone and anitmycin A, are serially injected to measure ATP
production, maximal respiration, and nonmitochondrial respi-
ration, respectively. Oligomycin inhibits ATP synthetase
(complex V), and FCCP is an uncoupling agent that collapses
the proton gradient and disrupts the mitochondrial membrane
potential. The OCR was measured in picomoles per minute and
was normalized by the number of cells in each well. For HeLa
cells, all antibiotics used led to a decrease in the maximal rate of
mitochondrial respiration (Figure 7A−C). Although the
treatment of HeLa cells with kanamycin did not exhibit a dose
dependence (Figure 7A), the treatment of HeLa cells with
levoﬂoxacin did exhibit a dose dependence (Figure 7B). With
regards to ethambutol, only 5Cmax led to a decrease in the
maximal rate of mitochondrial respiration (Figure 7C). For
BMDM, at Cmax, all antibiotics used in this study led to a drastic
decrease in the maximal mitochondrial respiratory capacity
(Figure 7D).
Taken together, our data suggest that kanamycin, levoﬂox-
acin, and ethambutol can induce mitochondrial dysfunction.
Our results are in accordance with results found in the
literature.6,51,52 However, only kanamycin impairs the CL:PI
ratio in a dose-dependent manner without aﬀecting cell viability
(Figures 2, 5, and 6). At this stage, from the use of ICL and
determination of the CL:PI ratio, our results demonstrate that
even if mitochondrial function was slightly impaired by the use
of antibiotics such as ethambutol or levoﬂoxacin at Cmax, there is
no direct correlation between mitochondrial dysfunction and
the CL:PI ratio. Only the aminoglycoside kanamycin can trigger
changes in the CL:PI ratio. Eﬀectively, our results based on the
ICL and CL:PI ratio are in line with those found in the literature
where aminoglycosides, including kanamycin, have been shown
to modulate phosphoinositide signaling and metabolism in the
cytoplasm and in the nucleus.53−58 We cannot rule out the
possibility that a decrease in the maximal rate of mitochondrial
oxygen consumption alter metabolic pathways; however, using
state-of-art metabolomics tools such as high-sensitivity and high-
resolution liquid chromatography−mass spectrometry-based
approaches will make this area exciting for future investigations.
■ CONCLUSION
Although the MALDI technique does not distinguish between
lipid isobaric species, i.e., complex lipids with the same mass but
diﬀerent fatty acid composition, the purpose of this study was to
provide a new approach for assessing antibiotic toxicity based on
the lipid proﬁle. By using MALDI-MS in the negative ion mode
directly on intact and unprocessed HeLa cells and BMDM cells,
we are able to perform targeted lipidomic proﬁling of PI and CL.
This is achieved using as few as 100−1000 cells per MALDI well
with limited sample preparation. Thus, this method represents a
major advance and can be used as an alternative to rapidly assess
as a screening assay the toxicity of a compound that interferes
with PI metabolism prior to in-depth analysis of the entire
lipidome using conventional lipidomics approaches such as the
ones presented earlier. We strongly believe that this method-
ology can go well beyond the scope of this study and can also be
applied to more cell types and purposes such as lipidome
remodeling to probe cancer diagnostics/metabolism and host−
pathogen interactions.
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